Aethl Bio

What Aethl Bio does

Aethl Bio, Inc. is a privately held, early-stage biotechnology company founded in Pittsburgh, Pennsylvania, by co-founders Carmelo R. Montalvo (CEO), Dan Willis (CTO), Zach Richert (VP, Strategy & Partnerships), and Derek Gonano (VP, Sales and Distribution). The company is developing an oxygen-based platform technology applied to chronic wound care and adjacent wellness applications, with a stated emphasis on functional healing (restoring skin integrity) rather than surface closure. Its lead commercial module is a proprietary hydrogel product line targeting chronic wounds including diabetic foot ulcers, pressure ulcers, and venous ulcers — a category in which only 3 of 70+ FDA-approved wound-care products address nonhealing wounds and where annual U.S. healthcare costs exceed $148B (per the company's framing) and pressure-ulcer costs exceed $28.6B (per the Sen 2025 compendium cited in its white paper).

Aethl Bio's technology architecture is platform-plus-modules: a core oxygen-based platform underpins the proprietary hydrogel product line, which is being advanced through a manufacturing and supply partnership with The Pure Source. The companies entered an MOU in April 2026 and executed a definitive long-term Manufacturing and Supply Agreement on June 18, 2026 to enable commercial-scale production. The company is pre-revenue and pre-commercial; no products are currently sold, pricing is not publicly disclosed, and the company's primary commercial outputs to date are a thought-leadership white paper ('A Wound that Won't Heal,' April 23, 2026), Scientific Advisory Board appointments (Dr. Joseph Maroon, Dr. Matthew Borrelli, Dan Marino, Laura Owen), and executive hires including a Chief Compliance Officer (Melissa A. Thompson, PhD). Customer contact is handled directly via [email protected] and (412) 202-6563, and go-to-market is being built around a sales-led motion targeting healthcare providers, industry partners, and clinical innovators.

Operationally, Aethl Bio describes itself as a small, lean, mission-driven team (1–10 employees) headquartered at 100 S Jackson Ave Ste 05-526, Pittsburgh, PA 15202-3907, with partnerships and operations across the United States. The company has raised $200,000 in a disclosed August 30, 2025 funding round (investors undisclosed), is hiring a Scientific Director, and has no disclosed patents, FDA clearances, named customers, or revenue. Key data gaps include funding beyond the initial $200K round, ownership/cap-table detail, regulatory milestones, and any clinical trial or commercial launch timeline.

Name

Aethl Bio

Legal name

Aethl Bio, Inc.

Website

https://aethl.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Aethl Bio is a pre-commercial Pittsburgh-based biotechnology company developing a proprietary oxygen-based platform and hydrogel product line for chronic wound care and adjacent wellness applications, targeting healthcare providers, Medicare-affected chronic-wound patients, and strategic partners ahead of product commercialization.

Ownership category

akta.pro rank

Headquarters

HQ city

Pittsburgh

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Commercial product sales (pre-launch): Pre-revenue / not yet commercialized. Definitive manufacturing and supply agreement with The Pure Source (executed June 18, 2026 from April 2026 MOU) is intended to enable commercial-scale production of Aethl's proprietary hydrogel product line. Expected model is sale of wound-care hydrogel products to healthcare providers and partners.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Aethl Bio is developing an oxygen-based platform technology and a proprietary hydrogel product line for chronic wound care and adjacent wellness applications. The company's core thesis is function-focused healing — restoring skin integrity rather than merely closing the wound surface — to address chronic non-healing wounds such as diabetic foot ulcers, pressure ulcers, and venous ulcers. Commercial-scale production is being enabled through a definitive manufacturing and supply partnership with The Pure Source.

Product overview

Aethl Bio's offering is a platform-plus-modules architecture built around its core Oxygen-Based Platform Technology for chronic wound care and wellness applications. On top of this core platform, the company is developing a Proprietary Hydrogel Product Line as a key commercial module, advanced through a manufacturing and supply partnership with The Pure Source (definitive agreement executed June 2026). The platform and hydrogel line together address the company's patient-centered, science-driven, function-focused healing thesis, supported by thought-leadership publications such as the "A Wound that Won't Heal" white paper.

Differentiator

Problem solved

Functional benefit

Products and services

• Oxygen-Based Platform Technology Aethl Bio's foundational platform technology that delivers oxygen-based therapy for chronic wound care and broader wellness applications. The platform underpins the company's product pipeline, including its hydrogel product line, and is positioned around patient-centered, science-driven, function-focused healing.
• Proprietary Hydrogel Product Line Aethl Bio's proprietary hydrogel product line being advanced through a manufacturing and supply partnership with The Pure Source. The hydrogel line is a key commercial product module within Aethl's oxygen-delivered wound care platform, targeting chronic wound treatment applications including diabetic foot ulcers, pressure ulcers, and venous ulcers.

Quantifiable outcome

• 1 in 6 Medicare beneficiaries suffer from a chronic wound; 1 in 5 diabetic foot ulcers results in amputation
• +1 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• MiMedx: Public regenerative medicine company selling placental tissue allografts (EpiFix, AmnioFix) for chronic wound care and surgical recovery. Comparable as a biology-driven, function-focused chronic-wound therapeutics company, with Aethl targeting the same providers and patient populations.
• Organogenesis: Commercial-stage biotech specializing in advanced wound care biologics (e.g., Apligraf, Dermagraft) for chronic wounds including diabetic foot ulcers and venous ulcers — directly comparable to Aethl's chronic-wound focus, with Aethl aiming to enter the same category with a hydrogel- and oxygen-based platform.

Broad incumbents

• Smith+Nephew: Global medical device incumbent with a major Advanced Wound Management portfolio (ALLEVYN, PICO, Oasis). Competes directly with Aethl's hydrogel line in hospital and home-health channels and defines the standard Aethl must beat on clinical evidence and distribution.
• Mölnlycke Health Care: Private global wound-care and surgical solutions company behind Mepilex and Mepitel. A key incumbent Aethl must displace in pressure-ulcer and chronic-wound protocols, with deep hospital contracting and clinical evidence.
• ConvaTec: Large wound-care-focused medical device company with hydrocolloid, hydrogel, and antimicrobial dressings (AQUACEL, DuoDERM). The most direct incumbent benchmark for Aethl's hydrogel product positioning in chronic wound care.
• Coloplast: Global leader in ostomy and wound care with a dedicated Wound & Skin Care business (Biatain, Comfeel). Competes with Aethl in chronic-wound dressings and represents the standard of international scale and clinical data Aethl must match.
• Integra LifeSciences: Broadly diversified medical technology company with a sizeable wound-care franchise (Integra Dermal Regeneration Template, PriMatrix, amniotic products). A direct competitor in advanced wound care and a benchmark for what Aethl must out-execute to win formulary access.
• 3M Health Care (Solventum): Diversified healthcare giant with a significant wound-care dressings portfolio (Tegaderm). Represents one of the entrenched incumbents whose distribution depth, formulary contracts, and pricing power set the competitive ceiling Aethl must navigate against.

Emerging players

• Axio Biosolutions: Emerging medtech company built around hydrogel-based hemostatic and wound-care products (e.g., Axiostat). Closely comparable to Aethl on hydrogel chemistry and target applications, though currently more advanced in trauma and surgical bleeding than chronic wounds.
• Carmell Therapeutics: Clinical-stage regenerative medicine company developing bioactive wound-care and orthobiologic products from allogeneic plasma. Comparable as a small, biology-forward wound-care player chasing the same function-focused healing thesis Aethl is positioning around.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/aethlbio
• Xx.com/aethlbio
• Facebookfacebook.com/aethlbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aethl Bio